Fragile X syndrome
Fragile X syndrome is the most common inherited cause of intellectual disability and autism features. It results from the loss of function of the FMR1 gene.
Fragile X syndrome (FXS) affects about one in 4,000 males and one in 9,000 females.
It is caused by an expanded CGG repeat (more than 199 repeats) in the FMR1 gene. This in turn causes a chemical change to DNA called methylation that silences the gene. A smaller sequence of 55 to 199 CGG repeats in the FMR1 gene is known as premutation. Premutations are common and are found in about one in 700 males and one in 300 females. Women who have a premutation are at risk of having children affected with FXS.
Diagnosis is by a genetic test usually ordered by a paediatrician. Early diagnosis enables early interventions and genetic counselling. All people planning a pregnancy or in the first trimester of a pregnancy can access fragile X carrier screening free of charge. This can be accessed through a new Medicare funded pathology test.
Who does it affect?
Who does it affect?
- In Australia, about one in 4,000 boys and one in 9,000 girls have Fragile X syndrome.
- Fragile X syndrome occurs in children of all ethnic backgrounds.
- More than 7,000 Australians have Fragile X syndrome.
- More than 50,000 Australian women are at risk of having children with Fragile X syndrome because they have a premutation.
Our Fragile X syndrome research
Our Fragile X syndrome research
We are working on the development of new tests to enable earlier diagnosis, including newborn screening. These tests may be able to predict future problems with health and development and detect children who are missed by existing tests.
Our researchers developed a world-first test that can detect Fragile X syndrome at birth. We are studying how often the syndrome occurs and how well this test works in the world’s largest Fragile X trial involving 100,000 newborns.
We are using qualitative interviews to understand the needs and experiences of adult female premutation carriers.
Impacts of our research
Impacts of our research
- Fragile X syndrome is estimated to cost the Australian economy up to $180 million a year, or $2.5 million per affected child.
- We have developed world-first genetic tools that could enable the inclusion of Fragile X as part of the newborn heel-prick test. If the condition is detected early as part of newborn screening, it would give families more options for the future. This includes quicker access to treatments and the option to have unaffected children through preimplantation genetic diagnosis (PGD) during IVF.
- We are also collecting information on the cost of raising a child with Fragile X to show the government that routine screening is cost-effective.
- Our work with adult female premutation carriers is being conducted with the goal of ultimately informing the development of an evidence-based national standard of care for this group, with carefully planned dissemination that is effective, ethical and meaningful.
Our vision
Our vision
Our vision is to effectively diagnose and build national consistent frameworks around the care and management of Fragile X as early as possible. This will enable timely access to interventions and treatments that improve life for children affected by this complex syndrome. It will also provide accurate advice to their families from birth, allowing them to make informed future reproductive decisions.
Get the latest information
Research trials key to finding better treatments for Fragile X
Read moreShare //
